RDS-127

Today, RDS-127 is a topic of great relevance that covers different areas of daily life. From its impact on society to its influence on the economy, RDS-127 is a topic that has sparked the interest of experts and citizens alike. With the advancement of technology and globalization, RDS-127 has become a ubiquitous issue that not only affects one country or region, but has global repercussions. In this article, we will explore different aspects related to RDS-127, from its origin to its projection in the future, with the aim of understanding its importance and impact today.

RDS-127
Structural formula of RDS-127
Ball-and-stick model of the RDS-127 molecule
Clinical data
ATC code
  • none
Identifiers
  • 4,7-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H27NO2
Molar mass277.408 g·mol−1
3D model (JSmol)
  • CCCN(CCC)C1CC2=C(C=CC(=C2C1)OC)OC
  • InChI=1S/C17H27NO2/c1-5-9-18(10-6-2)13-11-14-15(12-13)17(20-4)8-7-16(14)19-3/h7-8,13H,5-6,9-12H2,1-4H3 ☒N
  • Key:FPAHQTSJKYIURQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

RDS-127 is a drug which is used in scientific research. It acts as a D2-like receptor agonist[1] and also has some serotonin and adrenergic agonist effects,[2][3][4][5] as well as some anticholinergic action,[6][7] and produces both anorectic and pro-sexual effects in animal studies.[8][9]

See also

References

  1. ^ Arnerić SP, Long JP, Williams M, et al. (January 1983). "RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist". The Journal of Pharmacology and Experimental Therapeutics. 224 (1): 161–70. PMID 6401334.
  2. ^ Arnerić SP, Roetker A, Long JP, Mott J, Barfknecht CF (June 1982). "Effects of semirigid methoxamine analogs on vascular smooth muscle: studies of methoxy-2-aminotetralin and 2-aminoindane derivatives". Archives Internationales de Pharmacodynamie et de Thérapie. 257 (2): 263–73. PMID 7114973.
  3. ^ Arnerić SP, Long JP (May 1984). "Evidence that a novel dopamine receptor agonist, RDS-127 has some centrally mediated cardiovascular actions". The Journal of Pharmacy and Pharmacology. 36 (5): 318–21. doi:10.1111/j.2042-7158.1984.tb04382.x. PMID 6145768. S2CID 24354158.
  4. ^ Clark JT, Smith ER (1986). "Failure of pimozide and metergoline to antagonize the RDS-127-induced facilitation of ejaculatory behavior". Physiology & Behavior. 37 (1): 47–52. doi:10.1016/0031-9384(86)90382-3. PMID 3737722. S2CID 24423685.
  5. ^ Rezaki YE, Ilhan M (1991). "Evaluation of alpha-adrenoceptor agonistic activity of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in rabbit and rat aortae". Archives Internationales de Pharmacodynamie et de Thérapie. 310: 76–86. PMID 1685313.
  6. ^ Sahin I, Ilhan M (1988). "The antimuscarinic activity of a dopamine receptor agonist (RDS-127) differentiates M2-muscarinic receptors of heart, ileum and trachea in guinea-pig". Archives Internationales de Pharmacodynamie et de Thérapie. 296: 163–72. PMID 2907277.
  7. ^ Sahin I, Tuncer M, Ilhan M (March 1990). "Dopamine receptor agonists, N,N-dipropyl-2-aminotetralin (TL-68) and 2-di-n-propylamino-4,7-dimethoxyindane (RDS-127) antagonize oxotremorine-induced tremors by antimuscarinic action in mice". Archives Internationales de Physiologie et de Biochimie. 98 (1): 7–9. doi:10.3109/13813459009115730. PMID 1692697.
  8. ^ Arnerić SP, Roetker A, Long JP (September 1982). "Potent anorexic-like effects of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in the rat: a comparison with other dopamine-receptor agonists". Neuropharmacology. 21 (9): 885–90. doi:10.1016/0028-3908(82)90080-6. PMID 6897285. S2CID 12005863.
  9. ^ Kwong LL, Smith ER, Davidson JM, Peroutka SJ (October 1986). "Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors". Behavioral Neuroscience. 100 (5): 664–8. doi:10.1037/0735-7044.100.5.664. PMID 2877677.